Fig. 5: Drug-target MR estimates of GIPR and GLP1R agonism on liver disease risk and serum enzyme levels. | Molecular Psychiatry

Fig. 5: Drug-target MR estimates of GIPR and GLP1R agonism on liver disease risk and serum enzyme levels.

From: Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study

Fig. 5

This figure presents MR estimates assessing the effects of GIPR, GLP1R, and dual GIPR/GLP1R agonism on the multi-trait NAFLD GWAS (see Methods), serum alanine aminotransferase levels, aspartate aminotransferase, and serum gamma-glutamyl transpeptidase levels. Results are shown separately for genetically proxied reductions in BMI and HbA1c levels, two primary mechanisms through which these agonists exert their clinical effects. Beta values and 95% confidence intervals (CI) are displayed, with MR estimates derived from biomarker (BMI or HbA1c) data using the primary and independent replication data sources (described in the Methods and Table 1). GIPR glucose-dependent insulinotropic polypeptide receptor, GLP1R Glucagon-like peptide-1 receptor, HbA1c glycated hemoglobin; BMI body mass index, CI confidence interval.

Back to article page